Kinfo
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc.

INBXNASDAQHealthcare·US · USD
$95.01
+2.25 (+2.43%)
Prices as of October 9, 2026 · market closed

Price

Key statistics

Valuation
Market cap1.40B USD
Enterprise value1.42B USD
Trailing P/E0.20
Forward P/E-10.85
PEG ratio0.01
Price / sales1,075.63
Price / book-28.13
Profitability
Gross margin0.00%
Operating margin-9835.15%
Profit margin0.00%
Return on assets-43.61%
Return on equity-1773.60%
Income (TTM)
Revenue1.30M USD
Gross profit-103.00M USD
EBITDA-125.60M USD
Net income-138.18M USD
Diluted EPS-$8.88
Rev. growth (YoY)0.00%
Balance sheet
Total cash133.34M USD
Total debt181.63M USD
Debt / equity-3.43
Current ratio5.07
Book value / share-$3.60
Cash flow (TTM)
Operating cash flow-131.89M USD
Levered free cash flow-85.10M USD
Shares & price
Shares outstanding14.71M
Float8.59M
Held by institutions90.64%
Beta3.82
50-day MA$103.21
200-day MA$91.30
52-week high$155.29
52-week low$28.16
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-13-2.28-2.34−2.63%2026-07-200.340.36+5.88%2026-05-14-1.20-2.15−79.17%2026-03-19-2.08-2.11−1.44%
About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered biologic therapies for oncology and other serious diseases. Inhibrx Biosciences uses proprietary protein engineering platforms to design multivalent therapeutic candidates that are intended to interact precisely with complex biological targets. Its current pipeline centers on ozekibart (INBRX-109) and INBRX-106, programs being advanced in clinical studies across solid tumors and rare cancer settings. The company’s work is directed toward creating targeted medicines that address difficult-to-treat conditions through differentiated biologic mechanisms. Headquartered in La Jolla, California, Inhibrx Biosciences plays a specialized role in the biopharmaceutical market as a developer of precision protein-based therapeutics.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Mark Paul Lappe
Employees
109
Headquarters
La Jolla, CA, United States

Frequently asked questions about Inhibrx Biosciences, Inc.